Altimmune (ALT) Income towards Parent Company: 2010-2025
Historic Income towards Parent Company for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$19.0 million.
- Altimmune's Income towards Parent Company rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 18.82%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
- Altimmune's Income towards Parent Company amounted to -$19.0 million in Q3 2025, which was up 14.14% from -$22.1 million recorded in Q2 2025.
- Altimmune's 5-year Income towards Parent Company high stood at -$14.9 million for Q1 2021, and its period low was -$33.5 million during Q3 2021.
- Moreover, its 3-year median value for Income towards Parent Company was -$22.1 million (2025), whereas its average is -$22.2 million.
- Per our database at Business Quant, Altimmune's Income towards Parent Company tumbled by 282.54% in 2021 and then rose by 29.83% in 2022.
- Quarterly analysis of 5 years shows Altimmune's Income towards Parent Company stood at -$23.9 million in 2021, then grew by 9.33% to -$21.7 million in 2022, then crashed by 46.08% to -$31.6 million in 2023, then rose by 26.37% to -$23.3 million in 2024, then rose by 16.77% to -$19.0 million in 2025.
- Its Income towards Parent Company stands at -$19.0 million for Q3 2025, versus -$22.1 million for Q2 2025 and -$19.6 million for Q1 2025.